Cargando…
Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157036/ https://www.ncbi.nlm.nih.gov/pubmed/35650183 http://dx.doi.org/10.1038/s41392-022-01041-8 |
| _version_ | 1784718562686926848 |
|---|---|
| author | Tai, Wanbo Chai, Benjie Feng, Shengyong Zhuang, Xinyu Ma, Jun Pang, Mujia Pan, Lin Yang, Zi Tian, Mingyao Cheng, Gong |
| author_facet | Tai, Wanbo Chai, Benjie Feng, Shengyong Zhuang, Xinyu Ma, Jun Pang, Mujia Pan, Lin Yang, Zi Tian, Mingyao Cheng, Gong |
| author_sort | Tai, Wanbo |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9157036 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-91570362022-06-02 Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant Tai, Wanbo Chai, Benjie Feng, Shengyong Zhuang, Xinyu Ma, Jun Pang, Mujia Pan, Lin Yang, Zi Tian, Mingyao Cheng, Gong Signal Transduct Target Ther Letter Nature Publishing Group UK 2022-06-01 /pmc/articles/PMC9157036/ /pubmed/35650183 http://dx.doi.org/10.1038/s41392-022-01041-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Tai, Wanbo Chai, Benjie Feng, Shengyong Zhuang, Xinyu Ma, Jun Pang, Mujia Pan, Lin Yang, Zi Tian, Mingyao Cheng, Gong Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title_full | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title_fullStr | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title_full_unstemmed | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title_short | Development of a ferritin-based nanoparticle vaccine against the SARS-CoV-2 Omicron variant |
| title_sort | development of a ferritin-based nanoparticle vaccine against the sars-cov-2 omicron variant |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9157036/ https://www.ncbi.nlm.nih.gov/pubmed/35650183 http://dx.doi.org/10.1038/s41392-022-01041-8 |
| work_keys_str_mv | AT taiwanbo developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT chaibenjie developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT fengshengyong developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT zhuangxinyu developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT majun developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT pangmujia developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT panlin developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT yangzi developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT tianmingyao developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant AT chenggong developmentofaferritinbasednanoparticlevaccineagainstthesarscov2omicronvariant |